Kerr on Oncology

 
 
  • Kiss of Death for Cancer Research?   Dr. David Kerr comments on an ESMO position paper reporting that unintended consequences of the European Union's proposed law on data protection may seriously hinder cancer research.
  • A Physician's Perspective on Assisted Suicide   Dr. David Kerr thoughtfully responds to news that religious leaders support a proposed UK law for physician-assisted suicide and ponders whether he could offer his cancer patients this option.
  • Cancer Risk Arithmetic: 25 x 25 = 37M   Dr. David Kerr reports that a 25% reduction in risk factors for noncommunicable diseases by 2025 could save 37 million lives, and urges physicians to work harder to help patients give up tobacco.
  • Taking CRC Screening to the Underserved   Dr. David Kerr discusses strategies for increasing CRC screening in underserved populations in the United States, as proposed by a coalition of experts in cancer control and prevention.
  • Vitamin D and Colon Cancer   David Kerr discusses a new 'umbrella review' of vitamin D studies from across the medical literature, and the potential implications for the prevention of colon cancer.
  • How Many Metastases Rule Out Ablation?   Dr. David Kerr reports on a study fueling the controversy about which CRC patients with unresectable liver mets who receive conversion chemotherapy are candidates for secondary resection or ablation.
  • An Ambulance Driver's Legacy to His Doctor Son   Dr. David Kerr recalls how his father pulled him away from chess and books and helped him attain an essential trait of a doctor -- from the front seat of his Glasgow ambulance.
  • Muscle Power to Cancer Patients   Muscle mass and function are reduced in cancer as a consequence of therapy, malnutrition, and physical inactivity. Dr. David Kerr sees reason enough to prescribe exercise in addition to chemo.
  • Colorectal Data Varied and 'Very Rich'   Dr. David Kerr highlights CRC studies to be presented at ASCO, offering new data on first-line treatment, maintenance therapy, and resection of the primary tumor in patients with stage IV disease.
  • Adjuvant Chemo for Rectal Cancer Patients?   Dr. David Kerr reports on a well-conducted, 10-year study showing no benefit in the use of adjuvant chemotherapy in rectal patients, but he's not ready to stop using adjuvant chemo in his patients.
  • Adjuvant Chemo: Timing Isn't Everything   Dr. David Kerr reviews data for the timing of adjuvant chemotherapy in pancreas, colorectal, and most breast cancers and concludes that a delay of 3 months is acceptable -- and possibly preferable.
  • Open-Access Science for Better Cancer Drugs   Dr. David Kerr says 90% of new cancer drugs 'fail.' To reverse this rate, he advocates a novel model for drug development in which science is shared in open-access, industry-academic partnerships.
  • Help in Choosing IV Nutrition in Cachectic Cancer   Should clinicians offer parenteral nutrition to cachectic cancer patients who are unable to eat? Dr. David Kerr reports on a study that provides important evidence for this controversial issue.
  • 60-Day Mortality Not a Measure of Chemo Safety   Dr. David Kerr reports on a study indicating that half of 60-day deaths after initiation of chemo in advanced colorectal cancer are due to disease progression, which can be predicted by 2 factors.
  • Chemo Doublet Ups Survival in Biliary Tract Cancer   Dr. David Kerr reports on compelling evidence that cisplatin plus gemcitabine provides significant survival benefit in patients with advanced biliary tract cancer.
  • Don't Cap Chemo Dose in Obese Cancer Patients   Dr. David Kerr reports on a literature review indicating that there is no rationale for arbitrary reductions of chemotherapy dosing in obese cancer patients.
  • With Raltitrexed, No Cardiac Toxicity   Dr. David Kerr reports on a study that provides solid support for the use of raltitrexed in patients with cardiac toxicity induced by 5-fluorouracil or capecitabine cancer regimens.
  • Stiff Upper Lip May Hurt UK Cancer Survival   Can British stoicism account for lower cancer survival rates in the UK vs Europe? Possibly, says Dr. David Kerr, who bemoans the poor UK showing after a 10-year initiative to improve survival.
  • Adjuvant Aspirin: Big Benefits for Some CRC Patients   Dr. David Kerr reports on a study providing more evidence that patients with PIK3CA-mutant colorectal cancer benefit most from adjuvant aspirin therapy, but awaits prospective trials for confirmation.
  • New Regimen for Elderly Patients With mCRC   Dr. David Kerr reports on a study in which bevacizumab/capecitabine significantly improved PFS in patients at least 70 years old with advanced colorectal cancer.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.